Navigation Links
Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis
Date:2/2/2008

1 for 90 mg comparison). Also at week 40, 66 percent and 73 percent of patients achieved PASI 90 after receiving either 45 mg ustekinumab or 90 mg ustekinumab, respectively, and response rates remained stable through week 52 with continued treatment, compared with 37 percent and 38 percent of patients switched to placebo.

"The Phase 3 efficacy and safety data for ustekinumab are extremely promising and offer hope to a patient population in need of additional therapeutic options," says Kim Papp, MD, PhD, Probity Medical Research, Waterloo, Ontario, and lead study investigator.

About the PHOENIX 1 Trial

PHOENIX 1 evaluated the efficacy and safety of ustekinumab in the treatment of 766 patients with chronic plaque psoriasis. Patients were randomized to receive subcutaneously administered ustekinumab or placebo. Patients randomized to receive ustekinumab received 45 mg or 90 mg doses at weeks 0 and 4 followed by the same dose every 12 weeks. Patients in the placebo group crossed over to receive either 45 mg or 90 mg doses of ustekinumab at weeks 12 and 16 and every 12 weeks thereafter. The primary endpoint of the study was the proportion of patients achieving PASI 75 at week 12. Patients responding to ustekinumab through week 40 were randomized to either continue treatment with ustekinumab or were switched to placebo.

Through week 12 (the placebo-controlled portion of the study) the percentages of study participants experiencing at least one adverse event (AE) were comparable between the placebo group (48 percent) and the ustekinumab 45 mg group (57 percent) and 90 mg group (51 percent). Those patients experiencing at least one serious AE were reported as follows: 1 percent and 2 percent of patients receiving 45 mg or 90 mg ustekinumab, respectively, compared with 2 percent of patients receiving placebo. After the randomization at week 40, 46 percent and 49 percent of patients continuing treatment with 45 mg and 90 mg ustekinumab, respectivel
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
2. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
3. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
4. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
5. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
6. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
7. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
8. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
9. Inverseon Announces Positive Phase IIa Asthma Study
10. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
11. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO , Dec. 18, 2014  RESMED INC. (NYSE: ... its second quarter of fiscal year 2015 results on Thursday, ... close. A press release with ResMed,s results will be issued ... host a webcast to discuss operating results and future outlook. ... 1:30 p.m. US Pacific Time and the live webcast of ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last month,s ... site now known as the leading online black market ... explosive growth in its offering of drugs and other ... show the takedowns did succeed in lowering the numbers ... review of the markets in August. But some new ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 /PRNewswire/ ... and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced ... insulin, known as BioChaperone Lispro, for treatment in people ... relies on Adocia,s proprietary BioChaperone® technology and is currently ... will develop BioChaperone Lispro with the goal of optimizing ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... 2011 Aethlon Medical, Inc. (OTCBB: AEMD), the ... infectious disease and cancer, announced today the introduction ... inhibit the progression of HER2+ breast cancer, which ... resulting from the over-expression of HER2 protein.  Breast ...
... that a new market research report is available in ... Market http://www.reportlinker.com/p0619259/Generic-Drugs-The-Global-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug ... generics market is estimated at about $225 billion in ... of the total global generics sector will have risen ...
Cached Medicine Technology:Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 2Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 3Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 4Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 5Generic Drugs: The Global Market 2Generic Drugs: The Global Market 3Generic Drugs: The Global Market 4Generic Drugs: The Global Market 5Generic Drugs: The Global Market 6Generic Drugs: The Global Market 7Generic Drugs: The Global Market 8Generic Drugs: The Global Market 9Generic Drugs: The Global Market 10Generic Drugs: The Global Market 11Generic Drugs: The Global Market 12
(Date:12/19/2014)... Kan. (PRWEB) December 19, 2014 B. ... exclusively to healthcare providers, has been retained to lead ... Estes Park Medical Center in Estes Park, Colo. The ... E. Smith has recently placed more than 900 healthcare ... (EPMC) is a 25-bed, not-for-profit critical access hospital and ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Hands On Mobile ... available. The Spa On Wheels has been transformed into ... from the outside world seems to disappear. The Virtual Tour ... massages, facials, spa parties, corporate events and more. , The ... Spa On Wheels which is actually an overhauled Winnebago. Marla ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 ... the diagnostic, personalized medicine, healthcare information technology, and ... the position of Chief Operating Officer. The announcement ... Partners, marked by a strengthened presence in Boston ... , "Leslie lives and breathes the client experience," ...
(Date:12/19/2014)... 19, 2014 The Hermitage Club ... in Southern Vermont’s Deerfield Valley, announced today that it ... classic rock songs. , Three time Grammy Award ... private concert followed by a trail naming ceremony. Hermitage ... names include: “I’m Alright” the theme song for the ...
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... to moms who were exposed to high levels of air ... developing autism, a U.S. study suggests. Researchers found that ... and 2002, those exposed to the most air pollution during ... later developed autism. And exposure during the third trimester, specifically, ...
Breaking Medicine News(10 mins):Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3
... ... , ... 15, 2009 -- Reproductive Medicine Associates of Connecticut (RMACT) fertility clinic and ... Museum in Norwalk, CT. The party, a reunion of sorts, celebrates RMACT,s impact in helping ...
... , , , , ... Action Network ( www.pancan.org ), the only national organization ... outreach and advocacy for a cure is mourning the loss of ... in early 2008 and his subsequent battle put a spotlight on ...
... MERIDEN, Conn., Sept. 14 Protein Sciences Corporation (PSC) announced ... motion to dismiss the involuntary bankruptcy case filed against it by ... not in the best interests of PSC and its creditors. , ... PSC , PSC is a privately held biopharmaceutical company ...
... NORTH CANTON, Ohio, Sept. 14 Drs. Stephanie and Stuart ... website takes on the big box stores in an effort to ... Industry. , , Important to the scope ... generation veterinarian Dr. Stephanie Pierce and her team offer to their ...
... , , , , ... the Cure, the world,s largest grassroots network of breast cancer survivors ... Nixon as San Diego,s 2009 Honorary Breast Cancer Survivor. Nixon, a ... overlooked by several doctors because of her age and uncommon symptoms. ...
... , , , ... America,s Service Men and Women , , ... meeting in Austin, TX, the full membership of the DNC passed ... service members. Under Democratic leadership, the Obama Administration and Congress are ...
Cached Medicine News:Health News:RMACT Celebrates Seven Years of Growing Families 2Health News:RMACT Celebrates Seven Years of Growing Families 3Health News:RMACT Celebrates Seven Years of Growing Families 4Health News:The Pancreatic Cancer Action Network Is Saddened by the Death of Actor Patrick Swayze 2Health News:Veterinarian Group Launches New Website to Help Pet Owners With Medical Advice and the Best Vet-Approved Products 2Health News:Young Survivor and Advocate, Amanda Nixon, Named 2009 Honorary Breast Cancer Survivor by Susan G. Komen for the Cure, San Diego 2Health News:Young Survivor and Advocate, Amanda Nixon, Named 2009 Honorary Breast Cancer Survivor by Susan G. Komen for the Cure, San Diego 3Health News:Young Survivor and Advocate, Amanda Nixon, Named 2009 Honorary Breast Cancer Survivor by Susan G. Komen for the Cure, San Diego 4Health News:DNC Commends Policies That Are Making a Difference in the Lives of Military Families 2Health News:DNC Commends Policies That Are Making a Difference in the Lives of Military Families 3
... areas of cardiac anesthesia, cardiac ... it is essential to include ... motorized TEE transducer with Steerable ... Echo technology allows imaging frequencies ...
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... The 5548 is our High Penetration Steered ... ranging from 3 to 8 MHz. ... offering Pure Harmonic Detection with 4 different ... or deeper vessels. The high color and ...
... alternative to the UST-995-7.5 for those surgeons ... a "transverse view in relation to the ... This is a Super High Density, multi-frequency ... nestles comfortably between your index and middle ...
Medicine Products: